Diabetes Care, Vol 23, Issue 5 639-643, Copyright © 2000 by American Diabetes Association

ARTICLES

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes

RE Ratner, IB Hirsch, JL Neifing, SK Garg, TE Mecca and CA Wilson
MedStar Clinical Research Center, Washington, DC, USA. rratner@compuserve.com

OBJECTIVE: Insulin glargine (21A-Gly-30Ba-L-Arg-30Bb-L-Arg-human insulin) is a biosynthetic insulin analog with a prolonged duration of action compared with NPH human insulin. This study compared insulin glargine with NPH human insulin in subjects with type 1 diabetes who had been previously treated with multiple daily injections of NPH insulin and regular insulin. RESEARCH DESIGN AND METHODS: This study was a multicenter randomized parallel-group study in which subjects were randomized to receive premeal regular insulin and either insulin glargine (at bedtime) or NPH insulin (at bedtime for patients on once-daily therapy and at bedtime and in the morning for patients on twice-daily therapy) for up to 28 weeks. Dose titration of both basal insulins was based on capillary fasting whole blood glucose (FBG) levels; the goal was a premeal blood glucose concentration of 4.4-6.7 mmol/l. RESULTS: A total of 534 well-controlled type 1 diabetic subjects (mean GHb 7.7%, mean fasting plasma glucose [FPG] 11.8 mmo/l) were treated. A small decrease in GHb levels was noted with both insulin glargine (-0.16%) and NPH insulin (-0.21%; P > 0.05). Significant reductions in median FPG levels from baseline (-1.67 vs. -0.33 mmol/l with NPH insulin, P = 0.0145) and a trend for a reduction in capillary FBG levels were achieved with insulin glargine. After the 1-month titration phase, significantly fewer subjects receiving insulin glargine experienced symptomatic hypoglycemia (39.9 vs. 49.2%, P = 0.0219) or nocturnal hypoglycemia (18.2 vs. 27.1%, P = 0.0116) with a blood glucose level <2.0 mmol/l compared with subjects receiving NPH insulin. CONCLUSIONS: Lower FPG levels with fewer episodes of hypoglycemia were achieved with insulin glargine compared with once- or twice-daily NPH insulin as part of a basal-bolus regimen in patients with type 1 diabetes.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. C. Deeb Diabetes Technology During the Past 30 Years: A Lot of Changes and Mostly for the Better Diabetes Spectr, April 1, 2008; 21(2): 78 - 83. [Abstract] [Full Text] [PDF]

				K. Hassan, L. M. Rodriguez, S. E. Johnson, S. Tadlock, and R. A. Heptulla A Randomized, Controlled Trial Comparing Twice-a-Day Insulin Glargine Mixed With Rapid-Acting Insulin Analogs Versus Standard Neutral Protamine Hagedorn (NPH) Therapy in Newly Diagnosed Type 1 Diabetes Pediatrics, March 1, 2008; 121(3): e466 - e472. [Abstract] [Full Text] [PDF]

				S. Shalitin and M. Phillip Hypoglycemia in Type 1 Diabetes: A still unresolved problem in the era of insulin analogs and pump therapy Diabetes Care, February 1, 2008; 31(Supplement_2): S121 - S124. [Abstract] [Full Text] [PDF]

				J. C. Pickup and E. Renard Long-Acting Insulin Analogs Versus Insulin Pump Therapy for the Treatment of Type 1 and Type 2 Diabetes Diabetes Care, February 1, 2008; 31(Supplement_2): S140 - S145. [Abstract] [Full Text] [PDF]

				R. Taylor and J. M Davison Type 1 diabetes and pregnancy BMJ, April 7, 2007; 334(7596): 742 - 745. [Full Text] [PDF]

				M. F. Bullano, M. D. Fisher, W. D. Grochulski, L. Menditto, and V. J. Willey Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products Am. J. Health Syst. Pharm., December 15, 2006; 63(24): 2473 - 2482. [Abstract] [Full Text] [PDF]

				A. T. Soliman, M. Omar, M. M. Rizk, A. El Awwa, and F. M. AlGhobashy Glycaemic Control with Modified Intensive Insulin Injections (MII) Using Insulin Pens and Premixed Insulin in Children with Type-1 Diabetes: A Randomized Controlled Trial J Trop Pediatr, August 1, 2006; 52(4): 276 - 281. [Abstract] [Full Text] [PDF]

				V. J. Briscoe and S. N. Davis Hypoglycemia in Type 1 and Type 2 Diabetes: Physiology, Pathophysiology, and Management Clin. Diabetes, July 1, 2006; 24(3): 115 - 121. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Insulin Treatment and Type 1 Diabetes Topics Diabetes Care, April 1, 2006; 29(4): 936 - 944. [Full Text] [PDF]

				G. Di Cianni, L. Volpe, C. Lencioni, K. Chatzianagnostou, I. Cuccuru, A. Ghio, L. Benzi, and S. Del Prato Use of Insulin Glargine During the First Weeks of Pregnancy in Five Type 1 Diabetic Women Diabetes Care, April 1, 2005; 28(4): 982 - 983. [Full Text] [PDF]

				I. B. Hirsch Insulin Analogues N. Engl. J. Med., January 13, 2005; 352(2): 174 - 183. [Full Text] [PDF]

				Y. C. Kudva, A. Basu, G. D. Jenkins, G. M. Pons, L. L. Quandt, J. A. Gebel, D. A. Vogelsang, S. A. Smith, R. A. Rizza, and W. L. Isley Randomized Controlled Clinical Trial of Glargine Versus Ultralente Insulin in the Treatment of Type 1 Diabetes Diabetes Care, January 1, 2005; 28(1): 10 - 14. [Abstract] [Full Text] [PDF]

				J. Silverstein, G. Klingensmith, K. Copeland, L. Plotnick, F. Kaufman, L. Laffel, L. Deeb, M. Grey, B. Anderson, L. A. Holzmeister, et al. Care of Children and Adolescents With Type 1 Diabetes: A statement of the American Diabetes Association Diabetes Care, January 1, 2005; 28(1): 186 - 212. [Full Text] [PDF]

				A. Duttaroy, P. Kanakaraj, B. L. Osborn, H. Schneider, O. K. Pickeral, C. Chen, G. Zhang, S. Kaithamana, M. Singh, R. Schulingkamp, et al. Development of a Long-Acting Insulin Analog Using Albumin Fusion Technology Diabetes, January 1, 2005; 54(1): 251 - 258. [Abstract] [Full Text] [PDF]

				I. Gallen Review: The evolution of insulin treatment in type 1 diabetes: the advent of analogues The British Journal of Diabetes & Vascular Disease, November 1, 2004; 4(6): 378 - 381. [Abstract] [PDF]

				Update on insulin analogues DTB, October 1, 2004; 42(10): 77 - 80. [Abstract] [Full Text] [PDF]

				S.A. Saunders, M. Wallymahmed, and I.A. MacFarlane Glycaemic control in a type 1 diabetes clinic for younger adults QJM, September 1, 2004; 97(9): 575 - 580. [Abstract] [Full Text] [PDF]

				P. Home, P. Bartley, D. Russell-Jones, H. Hanaire-Broutin, J.-E. Heeg, P. Abrams, M. Landin-Olsson, B. Hylleberg, H. Lang, and E. Draeger Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes: A randomized clinical trial Diabetes Care, May 1, 2004; 27(5): 1081 - 1087. [Abstract] [Full Text] [PDF]

				K. K. Daugherty Review of Insulin Therapy Journal of Pharmacy Practice, February 1, 2004; 17(1): 10 - 19. [Abstract] [PDF]

				S. Clement, S. S. Braithwaite, M. F. Magee, A. Ahmann, E. P. Smith, R. G. Schafer, and I. B. Hirsch Management of Diabetes and Hyperglycemia in Hospitals Diabetes Care, February 1, 2004; 27(2): 553 - 591. [Full Text] [PDF]

				C. L Acerini and A. Deeb Review: New approaches to insulin therapy in children and adolescents with type 1 diabetes The British Journal of Diabetes & Vascular Disease, January 1, 2004; 4(1): 16 - 20. [Abstract] [PDF]

				I. W. Gallen and C. Carter Prospective Audit of the Introduction of Insulin Glargine (Lantus) Into Clinical Practice in Type 1 Diabetic Patients Diabetes Care, December 1, 2003; 26(12): 3352 - 3353. [Full Text] [PDF]

				A. Hamann, S. Matthaei, C. Rosak, and L. Silvestre A Randomized Clinical Trial Comparing Breakfast, Dinner, or Bedtime Administration of Insulin Glargine in Patients With Type 1 Diabetes Diabetes Care, June 1, 2003; 26(6): 1738 - 1744. [Abstract] [Full Text] [PDF]

				P. E. Cryer, S. N. Davis, and H. Shamoon Hypoglycemia in Diabetes Diabetes Care, June 1, 2003; 26(6): 1902 - 1912. [Abstract] [Full Text] [PDF]

				D. E. DeWitt and I. B. Hirsch Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review JAMA, May 7, 2003; 289(17): 2254 - 2264. [Abstract] [Full Text] [PDF]

				D. E. DeWitt and D. C. Dugdale Using New Insulin Strategies in the Outpatient Treatment of Diabetes: Clinical Applications JAMA, May 7, 2003; 289(17): 2265 - 2269. [Abstract] [Full Text] [PDF]

				A. D. Morris Addressing Dosing Frequency in Diabetes: A Simple Approach to Improving Adherence to Therapy and Clinical Outcomes The Diabetes Educator, May 1, 2003; 29(3): 440 - 453. [PDF]

				P. Rossetti, S. Pampanelli, C. Fanelli, F. Porcellati, E. Costa, E. Torlone, L. Scionti, and G. B. Bolli Intensive Replacement of Basal Insulin in Patients With Type 1 Diabetes Given Rapid-Acting Insulin Analog at Mealtime: A 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime Diabetes Care, May 1, 2003; 26(5): 1490 - 1496. [Abstract] [Full Text] [PDF]

				G. Lepore, A. R. Dodesini, I. Nosari, and R. Trevisan Both Continuous Subcutaneous Insulin Infusion and a Multiple Daily Insulin Injection Regimen With Glargine as Basal Insulin Are Equally Better Than Traditional Multiple Daily Insulin Injection Treatment Diabetes Care, April 1, 2003; 26(4): 1321 - 1322. [Full Text] [PDF]

				P. Vague, J.-L. Selam, S. Skeie, I. De Leeuw, J. W.F. Elte, H. Haahr, A. Kristensen, and E. Draeger Insulin Detemir Is Associated With More Predictable Glycemic Control and Reduced Risk of Hypoglycemia Than NPH Insulin in Patients With Type 1 Diabetes on a Basal-Bolus Regimen With Premeal Insulin Aspart Diabetes Care, March 1, 2003; 26(3): 590 - 596. [Abstract] [Full Text] [PDF]

				N. P. Murphy, S. M. Keane, K. K. Ong, M. Ford-Adams, J. A. Edge, C. L. Acerini, and D. B. Dunger Randomized Cross-Over Trial of Insulin Glargine Plus Lispro or NPH Insulin Plus Regular Human Insulin in Adolescents With Type 1 Diabetes on Intensive Insulin Regimens Diabetes Care, March 1, 2003; 26(3): 799 - 804. [Abstract] [Full Text] [PDF]

				N. Younis, H. Soran, and D. Bowen-Jones Insulin glargine: a new basal insulin analogue QJM, November 1, 2002; 95(11): 757 - 761. [Full Text] [PDF]

				J. H. DeVries, F. J. Snoek, P. J. Kostense, N. Masurel, and R. J. Heine A Randomized Trial of Continuous Subcutaneous Insulin Infusion and Intensive Injection Therapy in Type 1 Diabetes for Patients With Long-Standing Poor Glycemic Control Diabetes Care, November 1, 2002; 25(11): 2074 - 2080. [Abstract] [Full Text] [PDF]

				D. S. Schade and V. Valentine To Pump or Not to Pump Diabetes Care, November 1, 2002; 25(11): 2100 - 2102. [Full Text] [PDF]

				D. R. Owens Optimising glycaemic control -- the role of long-acting insulin analogues in basal insulin therapy The British Journal of Diabetes & Vascular Disease, September 1, 2002; 2(5): 403 - 406. [Abstract] [PDF]

				C. G. Fanelli, S. Pampanelli, F. Porcellati, P. Rossetti, P. Brunetti, and G. B. Bolli Administration of Neutral Protamine Hagedorn Insulin at Bedtime versus with Dinner in Type 1 Diabetes Mellitus To Avoid Nocturnal Hypoglycemia and Improve Control: A Randomized, Controlled Trial Ann Intern Med, April 2, 2002; 136(7): 504 - 514. [Abstract] [Full Text] [PDF]

				A. W. Norris and L. M.B. Laffel Avoiding Nocturnal Hypoglycemia: Consideration of an Extra Injection at Bedtime Ann Intern Med, April 2, 2002; 136(7): 547 - 549. [Full Text] [PDF]

				M. A. Adlersberg, S. Fernando, G. R. Spollett, and S. E. Inzucchi Glargine and Lispro: Two cases of mistaken identity Diabetes Care, February 1, 2002; 25(2): 404 - 405. [Full Text]

				P. E. Cryer and B. P. Childs Negotiating the Barrier of Hypoglycemia in Diabetes Diabetes Spectr, January 1, 2002; 15(1): 20 - 27. [Abstract] [Full Text] [PDF]

				Z. Vajo, J. Fawcett, and W. C. Duckworth Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs Endocr. Rev., October 1, 2001; 22(5): 706 - 717. [Abstract] [Full Text] [PDF]

				M. Saleh and G. Grunberger Hypoglycemia: An Excuse for Poor Glycemic Control? Clin. Diabetes, October 1, 2001; 19(4): 161 - 167. [Abstract] [Full Text] [PDF]

				D. S. Cooper and C. D. DeAngelis Diabetes Mellitus--A Call for Papers JAMA, August 22, 2001; 286(8): 968 - 969. [Full Text] [PDF]

				R. A. Guthrie, D. Hinnen, and B. P. Childs Glargine: A New Basal Insulin, A New Opportunity Diabetes Spectr, August 1, 2001; 14(3): 120 - 122. [Full Text] [PDF]

				R. Guthrie Is There a Need for a Better Basal Insulin? Clin. Diabetes, April 1, 2001; 19(2): 66 - 70. [Abstract] [Full Text] [PDF]

				The Role of Frequent Glucose Monitoring in Intensive Diabetes Management The Diabetes Educator, March 1, 2001; 27(2_suppl): 3 - 17. [PDF]